Home » Posts tagged with » cancer
LIPAC Oncology takes NMIBC treatment TBC-1002 into phase 2 A trial

LIPAC Oncology takes NMIBC treatment TBC-1002 into phase 2 A trial

Investigational NMIBC treatment TBC-1002 : LIPAC Oncology said that it has wrapped up a phase 1 clinical trial of TBC-1002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and has now initiated a phase 2 A clinical trial. The US pharma company, which is a subsidiary of California-based TesoRx Pharma, said that the phase […]

The Pritzker Organization invests in AI-driven Systems Oncology

Systems Oncology, which uses big data and AI to discover scientific insights into cancer biology, has secured an undisclosed investment from the Pritzker Family Business Interests advised by The Pritzker Organization (TPO) during the first closing of its Series B round. The new capital will be used for investing in discovery research and pre-clinical development […]

Continue reading …
Elicio raises $33m to advance lymph node-targeted immuno-therapies

US immuno-oncology company Elicio Therapeutics has raised $33 million through a Series B financing round to advance ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS), and other lymph node targeted immuno-therapies. Elicio Therapeutics said that it has established an international investor base which includes Clal Biotechnology Industries, Efung Capital, and Livzon Pharmaceutical Group. According to the […]

Continue reading …
Constellation doses first patient in phase 1 trial of CPI-0209 for cancer

Constellation Pharmaceuticals, a US clinical-stage biopharmaceutical company, has dosed the first patient in a Phase 1/2 clinical trial of CPI-0209, a second-generation EZH2 (enhancer of zeste homolog 2) inhibitor in cancer. The Phase 1 dose-escalation phase of the clinical trial will assess the efficacy of CPI-0209 monotherapy in advanced, relapsed solid tumor patients. With extended […]

Continue reading …
Varian introduces Ethos therapy – AI-powered cancer care delivery solution

Ethos therapy Varian : Varian, a cancer care technologies developer, has introduced Ethos therapy, an artificial intelligence (AI)-powered personalized cancer care delivery system in radiation oncology, as per the latest medical device news. Ethos therapy, designed to deliver adaptive treatment in a typical 15-minute timeslot, will target the tumor, reduce dose to healthy tissue and […]

Continue reading …
FeDeriCa clinical trial results : Phase 3 trial in HER2-positive breast cancer meets primary endpoint

FeDeriCa clinical trial results : Roche’s Genentech reported that the phase 3 FeDeriCa study evaluating the investigational fixed-dose combination (FDC) of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase in HER2-positive breast cancer met its primary endpoint. The Perjeta and Herceptin combination, which was subcutaneously injected in combination with intravenous (IV) chemotherapy, showed non-inferior levels of […]

Continue reading …
BioMed, University of California open cancer research center in San Diego

The University of California San Diego (UC San Diego) and BioMed Realty have opened the Center for Novel Therapeutics (CNT) – a new cancer research center at the former’s Science Research Park in San Diego, California. The cancer research center in San Diego, which spans 137,500sft, has been developed with an investment of $92 million […]

Continue reading …
MERU clinical trial : AbbVie ends Rova-T program in lung cancer

Following undesired results from the phase 3 MERU clinical trial, US biopharma company AbbVie has terminated the research and development program of Rovalpituzumab Tesirine (Rova-T), an investigational lung cancer drug. The MERU clinical trial is being closed over futility with the phase 3 study, which was assessing Rova-T as a first-line maintenance therapy for advanced […]

Continue reading …
Imago Systems, Mayo Clinic to advance ICE Reveal for breast imaging

US medical imaging company Imago Systems and Mayo Clinic have signed a know-how license agreement to collaborate on breast imaging with the academic medical center to support clinical trial development and oversee the former’s reader studies for mammography. The multi-year agreement signed by the parties will focus on clinical trial support for the ICE Reveal […]

Continue reading …
TRACON begins phase 1 TJD5 clinical trial in advanced solid tumors

TJD5 clinical trial : US biopharma company TRACON Pharmaceuticals has dosed the first patient in a US phase 1 clinical trial of I-Mab Biopharma’s CD73 antibody TJD5 (TJ004309) in patients with advanced solid tumors. TJD5 will be dosed in the early-stage trial as a single agent and also in combination with Roche’s PD-L1 antibody TECENTRIQ […]

Continue reading …
Page 1 of 6123Next ›Last »